PRESS RELEASE published on 09/11/2024 at 07:30, 2 years 1 month ago Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract Medincell appoints ROTHSCHILD MARTIN MAUREL for liquidity contract management on Euronext Paris, complying with AMF Decision 2021-01 Euronext Paris Liquidity Contract Rothschild Martin Maurel AMF Decision Medincell
BRIEF published on 09/05/2024 at 07:35, 2 years 1 month ago Medincell: Promising advances for injectable Olanzapine Schizophrenia Phase 3 Medincell Olanzapine Teva Pharmaceuticals
PRESS RELEASE published on 09/05/2024 at 07:30, 2 years 1 month ago Inside Information / Other news releases Teva provides update on pivotal Phase 3 of Olanzapine LAI by Medincell. Safety results on track for H2 2024. Potential innovative long-acting antipsychotic treatment Clinical Trials Phase 3 Medincell Teva Olanzapine LAI
BRIEF published on 08/20/2024 at 17:52, 2 years 2 months ago Terms of participation in the Medincell General Meeting Shareholders General Assembly Remote Voting Medincell Videoconference
PRESS RELEASE published on 08/20/2024 at 17:47, 2 years 2 months ago Terms of availability of the preparatory documents for the GM Medincell announces participation terms in the Combined General Meeting on September 12, 2024, including remote voting options, video conference for shareholders, and document availability Shareholders Combined General Meeting Remote Voting Medincell Participation Terms
BRIEF published on 06/28/2024 at 07:35, 2 years 4 months ago H.C. Wainwright & Co. Initiates MedinCell’s Coverage with "Buy" Recommendation FDA Approval BUY Rating Biopharmaceuticals H.C. Wainwright & Co. Medincell
PRESS RELEASE published on 06/28/2024 at 07:30, 2 years 4 months ago Inside Information / Other news releases H.C. Wainwright & Co. initiates coverage of MedinCell with a 'Buy' recommendation at €24 price target, reflecting +80% potential increase. MedinCell achieves milestones with FDA approvals, positive Phase 3 results, and collaboration with AbbVie FDA Approval Coverage Initiation H.C. Wainwright & Co. Medincell Pharmaceutical Sector
BRIEF published on 06/11/2024 at 09:05, 2 years 4 months ago Medincell Joins Euronext Tech Leaders Index Innovation Tech Sector Investor Visibility Medincell Euronext Tech Leaders
PRESS RELEASE published on 06/11/2024 at 09:00, 2 years 4 months ago Inside Information / Other news releases Medincell joins Euronext Tech Leaders, gaining access to a broad investor base and support services. CEO Christophe Douat highlights the company's growth and tech innovation leadership Tech Sector Financial Strategy Investor Base Medincell Euronext Tech Leaders
BRIEF published on 05/10/2024 at 18:05, 2 years 5 months ago Medincell announces details on capital and voting rights in accordance with regulations Euronext Paris Share Capital Voting Rights Financial Regulation Medincell
Published on 10/30/2026 at 23:35, 1 day 2 hours ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 3 hours ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 19:00, 1 day 7 hours ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 11 hours ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/31/2026 at 16:35, 9 hours 58 minutes ago SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 3 hours ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 1 day 7 hours ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 1 day 3 hours ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 12:00, 1 day 14 hours ago Capital increase through exercise of subscription rights